On July 2, 2026, European healthcare networks highlighted the role of parallel distribution directives under the European Medicines Agency (EMA) in securing supply chains for high-value oncology medicines. Sourcing specialized immunotherapies like Keytruda and Herceptin requires navigating complex import frameworks and guaranteeing strict GDP (Good Distribution Practice) compliance.

At Onco Medicine, we have optimized our European distribution routes to ensure clinical facilities from Germany to Luxembourg receive critical medicines on time and in perfect condition. Temperature monitoring from airport tarmac to clinic door is the foundation of our logistics chain.

Key European Cold-Chain Challenges

• Regulatory Harmonization: Navigating varying pharmaceutical import rules among EU member states requires extensive documentation, including Certificate of Analysis (COA) checks and custom clearing bonds.
• GDP Logistics Compliance: Maintaining a continuous 2–8°C environment during cross-border transit via air freight is essential for the stability of monoclonal antibodies.
• Real-time Telemetry: Using GPS-enabled data loggers to record temperature, humidity, and location updates minimizes the risk of supply chain disruptions.

Ensuring secure access to advanced oncology treatments is a collaborative effort. By aligning with international transport standards and validating every batch, Onco Medicine bridges the gap between manufacturers and clinics across Europe. We remain committed to supporting healthcare providers with transparent, reliable pharmaceutical logistics.